Shares of Bruker Corporation (BRKR) reached a new 52-week high of $94.86 on Mar 21 before closing the session marginally lower at $94.27.In the past year, this Zacks Rank #3 (Hold) stock has risen 25.9% against a 1.1% decline of the industry and the S&P 500 composite’s rise of 32.2%.Over the past five years, Bruker registered earnings growth of 13%, comparing favorably with the industry’s 5.1% rise. The company has an expected long-term earnings growth rate of 14.4%. Bruker’s earnings surpassed the Zacks Co ...

PharmaVentures与Phasefocus Holdings Limited合作 - PharmaVentures作为Phasefocus Holdings Limited的独家顾问，协助其被Bruker收购[1] - PharmaVentures的董事Adrian Dawkes表示，此次交易为Phasefocus股东带来了成功的结果，获得了Bruker的商业认可[3] Phasefocus的业务和产品 - Phasefocus是一家专注于成像、图像处理算法和成像平台的私人公司[2] - Phasefocus开发了一种名为Livecyte的新型光学显微镜[2]

It has been about a month since the last earnings report for Bruker (BRKR) . Shares have added about 15.7% in that time frame, outperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Bruker due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Bruker Q4 Earnings Top Estimates, Margins FallBruker Cor ...

Bruker Corporation (BRKR) appears in good shape, with its shares rising 20.7% since the fourth-quarter earnings release. The company continues to benefit from its innovative, high-performance product lines. The AI-driven semiconductor and advanced packaging metrology tools in the NANO group are performing well.The Zacks Rank #2 (Buy) stock has increased 20.7% since the last earnings release compared with the industry’s rise of 15%. The Medical sector has gained 3.6% in the said time frame. The company has a ...

Bruker Corporation (BRKR) recently announced its progress in immunopeptidomics, glycoproteomics and other CCS-enabled 4D-proteomics workflows at the 20th US Human Proteome Organization Congress 2024. The advances include improved machine-learning de novo sequencing (Novor V2.0), a novel high-performance monitoring digital-twin software (TwinScape), the new glyco-PASEF method for high-sensitivity glycopeptide analysis and access to Spectronaut 18 for users of Bruker ProteoScape — a GPU-powered software for r ...

收购信息 - Bruker Corporation成功完成收购Chemspeed Technologies AG，标志着Bruker在科学软件、研发和质量控制数字化以及实验室自动化领域的扩张[1] - Chemspeed将作为独立业务继续在Bruker内部运营，保持对行业领先的自动化实验室解决方案和客户服务的承诺[2] - Bruker致力于在自动化研发和质量控制实验室解决方案、实验室数字化和科学软件领域进行战略扩张和创新[2] 预期收益 - 预计Chemspeed在2024年剩余三个季度将接近盈亏平衡，每个季度约有1000万美元的收入[2] - 到2025年预计Chemspeed将对Bruker的非GAAP每股收益有2-3美分的增值[2] 公司使命 - Bruker通过高性能科学仪器和高价值分析和诊断解决方案帮助科学家进行突破性发现，提高人类生活质量[3]

Bruker Corporation (BRKR) recently entered into a definitive share purchase agreement with TecFin S.à r.l., a controlled affiliate of the pre-eminent private equity firm PAI Partners, to acquire ELITechGroup. However, the €870 million cash transaction excludes the carved-out ELITech clinical chemistry business.The transaction is expected to close in the second quarter of 2024, subject to regulatory approvals, the carve-out of the clinical chemistry business and other customary closing conditions. Upon closi ...

BRUKER CORPORATION ANNUAL REPORT ON FORM 10-K TABLE OF CONTENTS Part III Item 10 Directors, Executive Officers and Corporate Governance 111 Item 11 Executive Compensation 111 Item 12 Security Ownership of Certain Beneficial Owners and Management and Related Shareholder Matters 111 Item 13 Certain Relationships and Related Transactions, and Director Independence 111 Item 14 Principal Accountant Fees and Services 111 ITEM 1 BUSINESS BSI BioSpin Segment The BSI BioSpin Segment also offers a range of services, ...

Bruker公司产品进展 - Bruker公司的CALID集团最近取得了不错的进展，主要是因为对差异化仪器的强劲需求[2] - Bruker公司在2023年推出了timsTOF Ultra，提供了市场领先的灵敏度和吞吐量，扩展了肽覆盖范围，并在无偏见的4D单细胞系和组织蛋白质组学中提供更准确的定量[3] - Bruker公司在2023年第四季度推出了Hysitron TI 990 TriboIndenter，具有卓越的性能、自动化和生产力，用于纳米力学测试[7] Bruker公司业务发展 - Bruker公司早前收购了著名的功能性细胞生物学公司PhenomeX，这一交易扩大了Bruker在转化研究、临床研究和生物制药领域的业务，并有助于其Project Accelerate 2.0计划[8] Bruker公司财务状况 - Bruker公司在2023年第四季度的非GAAP毛利率表现受到外汇波动的不利影响，预计这将在2024年第一季度继续对Bruker构成压力，导致较软的运营利润预测[10] - Bruker公司的成本增长导致毛利率下降，这可能会影响公司的运营结果和现金流[12]

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today that Gerald Herman, Executive Vice President & CFO will present on behalf of the Company at the following investor conferences: Citi 2024 Unplugged Medtech and Life Sciences Access Day in New York City Thursday, February 29, 2024, at 8:45 a.m. Eastern Time TD Cowen 44th Annual Health Care Conference in Boston, MA Monday, March 4, 2024, at 9:50 a.m. Eastern Time Live audiovisual webcasts of the presentations will be avail ...